A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
18h
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...
What you need to know about the new rulesPatients with Parkinson's disease get zero benefit from taking a skinny jab despite ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
University of Tasmania and Parkinson's Research Foundation bridge gap in Parkinson's knowledge with first of its kind resourceFree online course ...
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Richard Balanson says when one suffers a disease "you begin to accumulate friends" who have their own story with the same ...
ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson's disease (PD). It is not known if ONAPGO is safe and effective in children. Do not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback